Scholarlink

<p>The use of nanotechnology to make nanoformulations/nanocarriers is a rapidly evolving field of study with the potential to fundamentally improve the treatment outcomes for diverse disease states. The use of nanoformulations allows for targeted drug delivery to diseased sites and reduced unwanted side effects. There have been many FDA-approved nanoformulations for the treatment of complex disease states such as advanced non‐small cell lung cancer, secondary metastatic breast cancer, primary metastatic pancreatic cancer, Kaposi’s sarcoma related to AIDS, ovarian cancer, multiple myeloma, leukemia, amyloidosis, and age-related macular degeneration. While most nanoformulations are approved for cancer therapy, FDA-approved nanoformulations are effectively employed to treat autoimmune disorders, metabolic disorders, ophthalmic conditions, neurological diseases, hematological disorders, and inflammatory diseases. Further, novel nanoformulations are in various phases of clinical development for endocrine disorders, complex cancers, skin, ocular, blood, nervous system, cardiovascular, immune, and inflammatory disorders.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recent advances and FDA approvals in nanoformulations for drug delivery

  • 期刊论文

  • 发表日期：

    2025年1月4日

查看全文
  • Anahita Asadi,
  • Onyinyechi Obidiro,
  • Rashidat Elesho,
  • Kafilat Agbaje,
  • Mohammadali Kochakzade,
  • Pradeep Kumar Karla

摘要

The use of nanotechnology to make nanoformulations/nanocarriers is a rapidly evolving field of study with the potential to fundamentally improve the treatment outcomes for diverse disease states. The use of nanoformulations allows for targeted drug delivery to diseased sites and reduced unwanted side effects. There have been many FDA-approved nanoformulations for the treatment of complex disease states such as advanced non‐small cell lung cancer, secondary metastatic breast cancer, primary metastatic pancreatic cancer, Kaposi’s sarcoma related to AIDS, ovarian cancer, multiple myeloma, leukemia, amyloidosis, and age-related macular degeneration. While most nanoformulations are approved for cancer therapy, FDA-approved nanoformulations are effectively employed to treat autoimmune disorders, metabolic disorders, ophthalmic conditions, neurological diseases, hematological disorders, and inflammatory diseases. Further, novel nanoformulations are in various phases of clinical development for endocrine disorders, complex cancers, skin, ocular, blood, nervous system, cardiovascular, immune, and inflammatory disorders.